

# ESMO ADVANCED COURSE PROGRAMME

## Role of CDK4-6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer

Jeddah, SA  
7 September 2024

---

**CO-CHAIRS** Giuseppe Curigliano, Italy  
Barbara Pistilli, France  
Meteb Al-Foheidi, Saudi Arabia

**SPEAKERS** Dario Trapani, Italy  
Michael Gnant, Austria  
Lucia Del Mastro, Italy

**MODERATORS** Majid Al Jahil, Saudi Arabia  
Hikmat Abdel-Razeq, Jordan  
Adhar Alsayed, Saudi Arabia  
Ahmed Alwabari, Saudi Arabia  
Marwan Al Hajeili, Saudi Arabia  
Abdullah Al Tuwairgi, Saudi Arabia  
Essam Murshid, Saudi Arabia

### LEARNING OBJECTIVES

---

- Understanding the function and biology of CDK4-6 in breast cancer
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the early and metastatic setting
- Assessing the clinical and genomic features for risk of relapse in early HR+/HER2 negative breast cancer
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
- Discussing clinical cancer cases to integrate use of CDK4-6 inhibitors in clinical practice.

### ACCREDITATION

---

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to [www.esmo.org](http://www.esmo.org).

### ACKNOWLEDGEMENTS

---

This event is supported by an unrestricted educational grant from

## Saturday, 7 September 2024

---

- 09:00-09:10 **Welcome and introduction**  
Meteb Al-Foheidi, SA  
Giuseppe Curigliano, IT and Barbara Pistilli, FR
- 09:10-10:45 **Session 1 – CDK4-6 inhibitors in early breast cancer**  
Moderator: Meteb Al-Foheidi, SA  
Moderator: Majid Al Jahil, SA
- 20' Risk stratification in HR positive / HER2 negative early breast cancer: Clinical, pathological and genomic features  
Michael Grant, AT
- 20' CDK4-6 inhibitors in patients with early HR positive / HER2 negative breast cancer: Successes and failures  
Giuseppe Curigliano, IT
- 20' Incorporating CDK 4-6 inhibitors in patients with high-risk HR positive/ HER2 negative early breast cancer: Challenging clinical scenarios with the use of PARP inhibitors and immune-checkpoint inhibitors  
Dario Trapani, IT
- 35' Discussion
- 10:45-11:15 Coffee Break**
- 11:15-12:50 **Session 2 – CDK4-6 inhibition in advanced breast cancer**  
Moderator: Hikmat Abdel-Razeq, JO  
Moderator: Adhar Alsayed, SA
- 20' Role of CDK4-6 inhibitors in patients with endocrine sensitive HR positive / HER2 negative metastatic breast cancer  
Barbara Pistilli, FR
- 20' Role of CDK 4-6 inhibitors in patients with endocrine resistant HR positive /HER2 negative metastatic breast cancer  
Lucia Del Mastro, IT
- 20' New agents and new combinations in endocrine resistant HR positive /HER2 negative metastatic breast cancer  
Giuseppe Curigliano, IT
- 35' Discussion
- 12:50-13:50 Lunch break**
- 13:50-14:50 **Session 3 – Biomarkers and clinical and pathological features of response to CDK 4-6 inhibitors**  
Moderator: Ahmed Alwabari, SA
- 20' New generation clinical trials with CDK 4-6 inhibitors in the adjuvant setting  
Dario Trapani, IT
- 20' Genomic and transcriptomic landscape of patients receiving CDK 4-6 inhibitors  
Lucia Del Mastro, IT

20' Discussion

14:50-15:25 **Clinical Practice Session – CDK4-6 Inhibitors in breast cancer**

Moderator: Marwan Al Hajeili, SA

20' Management of adverse events of CDK 4-6 inhibitors in early and metastatic breast cancer: Balancing efficacy and toxicity  
Barbara Pistilli, FR

15' Discussion

**15:25-16:00 Coffee Break**

16:00-17:00 **Workshop Session**

**Workshop 1 Molecular Tumor Board**

Moderator: Abdullah Al Tuwaigji, SA

Moderator: Essam Murshid, SA

30' Presentation of 3 cases by speaker and discussion  
30' Discussion

Giuseppe Curigliano, IT  
Dario Trapani, IT  
Micheal Grant, AT  
Lucia Del Mastro, IT  
Barbara Pistilli, FR

17:00-17:15 **Synthesis and wrap-up**